Pfizer general counsel is out

Share this article:

Pfizer's general counsel Amy Schulman is leaving the company. The drugmaker announced Tuesday that Schulman, who was supposed to head up the company's vaccines and oncology division, will not step into the role and is leaving her positions both as general counsel and as part of the company's executive leadership team.

Instead, Albert Bourla will be group president of the vaccines, oncology and consumer healthcare business when it becomes an official financial entity within Pfizer in 2014. Susan Silbermann has been named president of the global vaccines business. Titles for Bourla and Silbermann go into effect next year.

The company said Schulman's departure was part of a mutual agreement.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.